Advertisement

Topics

NovoCure, Ltd. Company Profile

22:07 EDT 25th September 2017 | BioPortfolio


News Articles [56 Associated News Articles listed on BioPortfolio]

Novocure™ Announces National Reimbursement for Optune in Austria

The decision marks Novocure's first national coverage policy Novocure (NASDAQ: NVCR) announced today it has signed a contract with the Federation of the Austrian Social Insurance Institutions whic...

Novocure to Report Second Quarter 2017 Financial Results

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2017 on Thursday, July 27, 2017, before the U.S.-based financial markets open....

Study begins for Novocure's Optune device, Roche's Avastin

The first patient in a Phase II pilot study of a combination of Novocure's Optune tumor-treating fields delivery device and R -More- 

FDA grants HUD designation for Novocure's TTFields delivery system

Novocure has obtained a humanitarian use device designation from the FDA for its Tumor Treating Fields delivery system for us -More- 

Novocure kündigt Datenpräsentationen für den ESMO-Kongress 2017 an

Novocure (NASDAQ: NVCR) gab heute bekannt, dass auf dem Kongress der Europäischen Gesellschaft für Medizinische Onkologie 2017 (European Society for Medical Oncology, ESMO) vom 8. bis zum 12. Sept.....

Novocure Announces Data Presentations at the American Society for Radiation Oncology's 2017 Annual Meeting

Late-breaking oral presentation to focus on Optune five-year survival and health-related quality of life data Novocure (NASDAQ:NVCR) announced today four presentations on Tumor Treating Fields (TT...

Novocure™ Receives Humanitarian Use Device Designation for Treatment of Pleural Mesothelioma

Monday, May 15th 2017 at 11:25am UTC ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) announced today that United States Food and Drug Administration (FDA) has designated it’s ...

NovoCure Announces Data Presentations At s 2017 Annual Meeting

Late-breaking oral presentation to focus on Optune five-year survival and health-related quality of life data ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)

This protocol is designed to generate and provide preliminary data to determine the safety and activity of combination therapy using tumor treating fields (TTFields; Optune(NovoTTF-100A); ...

TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma

Glioblastoma multiforme (GBM) is the most common and deadliest primary malignant neoplasm of the central nervous system in adults. Despite an aggressive multimodality treatment approach in...

Companies [3 Associated Companies listed on BioPortfolio]

NovoCure

Novocure is a private Jersey Isle oncology company pioneering a novel therapy for solid tumors called TTFields. Novocure US operations are based in Portsmouth, NH and New York, NY...

NovoCure Limited

NovoCure Limited is a private Jersey Isle oncology company pioneering a novel therapy for solid tumors called TTFields. Novocure’s US operations are based in Portsmouth, NH a...

NovoCure, Ltd.

More Information about "NovoCure, Ltd." on BioPortfolio

We have published hundreds of NovoCure, Ltd. news stories on BioPortfolio along with dozens of NovoCure, Ltd. Clinical Trials and PubMed Articles about NovoCure, Ltd. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of NovoCure, Ltd. Companies in our database. You can also find out about relevant NovoCure, Ltd. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record